Catherine Egan1,2, Haogang Zhu3, Aaron Lee4, Dawn Sim5,6, Danny Mitry1, Clare Bailey7, Robert Johnston8, Usha Chakravarthy9, Alastair Denniston10, Adnan Tufail1,2, Rehna Khan11, Sajjad Mahmood12, Geeta Menon13, Toks Akerele14, Louise Downey15, Martin McKibbin16, Atul Varma17, Aires Lobo18, Elizabeth Wilkinson19, Alan Fitt20, Christopher Brand21, Marie Tsaloumas22, Kaveri Mandal23, Vineeth Kumar24, Salim Natha25, David Crabb26. 1. Department of Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK. 2. Institute of Ophthlamology, London, UK. 3. City University, London, London, UK. 4. Department of Ophthalmology, University of Washington, Seattle, USA. 5. Department of Medical Retina, Moorfields Eye Hospital, London, UK. 6. Department of Cell Biology, UCL Institute of Ophthalmology, London, UK. 7. Bristol Eye Hospital, Bristol, UK. 8. Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. 9. Queens University, Belfast, UK. 10. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 11. Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK. 12. Manchester Royal Eye Hospital, Manchester, UK. 13. Eye Department, Frimley Park Hospital, Frimley, UK. 14. Hinchingbrooke Health Care NHS Trust, Huntingdon, Cambridgeshire, UK. 15. Department of Ophthalmology, Hull Royal Infirmary, Hull, UK. 16. Leeds, UK. 17. Mid Yorkshire Hospitals NHS Trust, Yorkshire, UK. 18. Moorfields Eye Hospital NHS Foundation Trust, London, London, UK. 19. Northern Devon Healthcare NHS Trust, Barnstaple, Devon, UK. 20. Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, Peterborough, UK. 21. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 22. Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 23. Department of Ophthalmology, Warrington and Halton Hospitals NHS Foundation Trust, Warrington, UK. 24. Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK. 25. Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK. 26. Division of Optometry & Visual Science, City University, London, UK.
Abstract
AIMS: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database. METHODS: Structured clinical data were anonymised and extracted from an electronic medical record from 19 participating UK centres: age at first injection, ETDRS visual acuity (VA), number of injections, ETDRS diabetic retinopathy (DR) and maculopathy grade at baseline and visits. The main outcomes were change in mean VA from baseline, number of injections and clinic visits and characteristics affecting VA change and DR grade. RESULTS: Data from 12 989 clinic visits was collated from baseline and follow-up for 3103 eyes. Mean age at first treatment was 66 years. Mean VA (letters) for eyes followed at least 2 years was 51.1 (SD=19.3) at baseline, 54.2 (SD: 18.6) and 52.5 (SD: 19.4) at 1 and 2 years, respectively. Mean visual gain was five letters. The proportion of eyes with VA of 72 letters or better was 25% (baseline) and 33% (1 year) for treatment naïve eyes. Eyes followed for at least 6 months received a mean of 3.3 injections over a mean of 6.9 outpatient visits in 1 year. CONCLUSIONS: In a large cohort of eyes with DMO treated with ranibizumab injections in the UK, 33% of patients achieved better than or equal to 6/12 in the treated eye at 12 months compared with 25% at baseline. The mean visual gain was five letters. Eyes with excellent VA at baseline maintain good vision at 18 months. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
AIMS: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database. METHODS: Structured clinical data were anonymised and extracted from an electronic medical record from 19 participating UK centres: age at first injection, ETDRS visual acuity (VA), number of injections, ETDRS diabetic retinopathy (DR) and maculopathy grade at baseline and visits. The main outcomes were change in mean VA from baseline, number of injections and clinic visits and characteristics affecting VA change and DR grade. RESULTS: Data from 12 989 clinic visits was collated from baseline and follow-up for 3103 eyes. Mean age at first treatment was 66 years. Mean VA (letters) for eyes followed at least 2 years was 51.1 (SD=19.3) at baseline, 54.2 (SD: 18.6) and 52.5 (SD: 19.4) at 1 and 2 years, respectively. Mean visual gain was five letters. The proportion of eyes with VA of 72 letters or better was 25% (baseline) and 33% (1 year) for treatment naïve eyes. Eyes followed for at least 6 months received a mean of 3.3 injections over a mean of 6.9 outpatient visits in 1 year. CONCLUSIONS: In a large cohort of eyes with DMO treated with ranibizumab injections in the UK, 33% of patients achieved better than or equal to 6/12 in the treated eye at 12 months compared with 25% at baseline. The mean visual gain was five letters. Eyes with excellent VA at baseline maintain good vision at 18 months. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
Macula; Public health; Retina; Treatment Medical; Treatment Surgery
Authors: Leonardo Mastropasqua; Silvio Di Staso; Rossella D'Aloisio; Alessandra Mastropasqua; Luca Di Antonio; Alfonso Senatore; Marco Ciancaglini; Marta Di Nicola; Giuseppe Di Martino; Daniele Tognetto; Lisa Toto Journal: Int J Ophthalmol Date: 2019-10-18 Impact factor: 1.779
Authors: Cecilia S Lee; Aaron Y Lee; Douglas Baughman; Dawn Sim; Toks Akelere; Christopher Brand; David P Crabb; Alastair K Denniston; Louise Downey; Alan Fitt; Rehna Khan; Sajad Mahmood; Kaveri Mandal; Martin Mckibbin; Geeta Menon; Aires Lobo; B Vineeth Kumar; Salim Natha; Atul Varma; Elizabeth Wilkinson; Danny Mitry; Clare Bailey; Usha Chakravarthy; Adnan Tufail; Catherine Egan Journal: Am J Ophthalmol Date: 2017-05-29 Impact factor: 5.258
Authors: Paul Mitchell; Tom G Sheidow; Michel E Farah; Sajjad Mahmood; Angelo M Minnella; Nicole Eter; Bora Eldem; Hassan Al-Dhibi; Wayne Macfadden; Soumil Parikh; Cornelia Dunger-Baldauf; Mohamed M Mahgoub; Ursula Schmidt-Erfurth Journal: PLoS One Date: 2020-06-03 Impact factor: 3.240
Authors: Laurent Kodjikian; Amélie Lecleire-Collet; Corinne Dot; Marie-Laure Le Lez; Stéphanie Baillif; Ali Erginay; Eric Souied; Eric Fourmaux; Philippe Gain; Anne Ponthieux Journal: Clin Ophthalmol Date: 2021-06-03